Department of Respiratory Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
Department of Hematology, Showa University Fujigaoka Hospital, Yokohama, Japan.
Lung Cancer. 2024 Aug;194:107869. doi: 10.1016/j.lungcan.2024.107869. Epub 2024 Jul 1.
Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is routinely prescribed as first-line therapy for advanced non-small cell lung cancer, regardless of the presence of the T790M resistance mutation. This study reports a rare case of Factor V inhibitor detection during osimertinib therapy in a patient with lung adenocarcinoma. These findings underscore the importance of vigilant monitoring for coagulation abnormalities during EGFR-TKI therapy.
奥希替尼是第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI），无论是否存在 T790M 耐药突变，均常规用于晚期非小细胞肺癌的一线治疗。本研究报告了一例肺腺癌患者在接受奥希替尼治疗期间检测到因子 V 抑制剂的罕见病例。这些发现强调了在 EGFR-TKI 治疗期间密切监测凝血异常的重要性。
